Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells

Journal: Journal of Experimental Medicine

Published: 2020-02-03

DOI: 10.1084/jem.20191009

Affiliations: 6

Authors: 22

Go to article
Institutions Share
Laboratory of Experimental Immunology, Osaka University, Japan 0.48
Faculty / Graduate School of Medicine, Akita University, Japan 0.20
Faculty / Graduate School of Medicine, Mie University, Japan 0.14
Klinik für Onkologie und Hämatologie, Krankenhaus Nordwest GmbH, Germany 0.09
Department of Hematology and Oncology, Kyoto University, Japan 0.05
Faculty / Graduate School of Medicine, Kyoto University, Japan 0.05

Return

Except where otherwise noted © 2020 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER